Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Phathom Pharmaceuticals (PHAT) Leases (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Leases for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 324.63% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 324.63% increase, with the full-year FY2025 number at $2.6 million, up 324.63% from a year prior.
  • Leases was $2.6 million for Q4 2025 at Phathom Pharmaceuticals, down from $2.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $2.7 million in Q3 2025 to a low of $388000.0 in Q1 2025.
  • A 4-year average of $1.7 million and a median of $1.7 million in 2022 define the central range for Leases.
  • Biggest YoY gain for Leases was 324.63% in 2025; the steepest drop was 69.3% in 2025.
  • Phathom Pharmaceuticals' Leases stood at $2.3 million in 2022, then tumbled by 35.51% to $1.5 million in 2023, then crashed by 58.44% to $613000.0 in 2024, then skyrocketed by 324.63% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Leases are $2.6 million (Q4 2025), $2.7 million (Q3 2025), and $873000.0 (Q2 2025).